Table 2.

Cox Proportional Hazard Model for Virological Relapse HBeAg-Positive Patients (n=122)

Variable	Univariate Analysis			Multivariable Analysis
	HR	95% CI	p-value	HR	95% CI	p-value
Age (years)	1.032	0.994–1.032	0.098	1.051	1.010–1.093	0.013
Male vs Female	1.127	0.541–2.346	0.750
First-line vs Second-line drugs†	0.702	0.388–1.271	0.242
Treatment duration, (years)	1.077	0.961–1.207	0.201
Consolidation treatment duration (years)	0.886	0.744–1.056	0.176	0.961	0.796–1.159	0.676
ALT (U/L)	0.982	0.952–1.013	0.255
HBsAg (log10 IU/mL)	1.328	0.970–1.818	0.077
≥100 IU/mL	3.842	1.374–100.743	0.010	4.406	1.567–12.389	0.005
<100 IU/mL	Ref
HBcrAg (log10 U/mL)	2.116	1.451–3.086	<0.001	2.105	1.440–3.077	<0.001
≥4.0 log10 U/mL	4.042	2.301–7.099	<0.001
<4.0 log10 U/mL	Ref

Notes: ^†First-line, entecavir, tenofovir; second-line, lamivudine, adefovir, telbivudine, and combination treatment.

Abbreviations: ALT, alanine aminotransferase; ULN, upper limit of normal; HBeAg, hepatitis B envelope antigen; HBsAg, hepatitis B surface antigen; HBcrAg, hepatitis B core-relative antigen; ns, no significance; HR, hazard ratio; 95% CI, 95% confidence interval.